Literature DB >> 8517726

9-Anilinoacridines as potential antileishmanial agents.

J Mauël1, W Denny, S Gamage, A Ransijn, S Wojcik, D Figgitt, R Ralph.   

Abstract

A number of 1'-substituted 9-anilinoacridines were evaluated for their activities against promastigote and amastigote forms of Leishmania major and for their toxicities to human Jurkat leukemia cells. Several compounds possessing 1'-NH-alkyl substituents produced more than 80% growth inhibition of macrophage-infected L. major amastigotes at or below a concentration of 1 microM. 1'-Hexylamino-9-anilinoacridine (compound 14) was the least toxic compound to human Jurkat cells, while it retained strong antileishmanial activity. There was a general trend for the more lipophilic compounds to show the greatest antileishmanial activity, whereas 3,6-di-NH2 substitution of the acridine nucleus reduced or eliminated activity. Some structure-activity relationships of the various compounds are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517726      PMCID: PMC187873          DOI: 10.1128/AAC.37.5.991

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.

Authors:  U Jehn; V Heinemann
Journal:  Anticancer Res       Date:  1991 Mar-Apr       Impact factor: 2.480

Review 2.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

3.  ATP-independent DNA topoisomerase II as potential drug target in trypanosomes.

Authors:  S Douc-Rasy; J F Riou; J C Ahomadegbe; G Riou
Journal:  Biol Cell       Date:  1988       Impact factor: 4.458

4.  Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.

Authors:  B C Baguley; K M Holdaway; L M Fray
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

5.  Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.

Authors:  L P Miller; A F Pyesmany; L J Wolff; P C Rogers; S E Siegel; R J Wells; J D Buckley; G D Hammond
Journal:  Cancer       Date:  1991-05-01       Impact factor: 6.860

6.  Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.

Authors:  G W Rewcastle; B C Baguley; G J Atwell; W A Denny
Journal:  J Med Chem       Date:  1987-09       Impact factor: 7.446

7.  Estimation of population at risk of infection and number of cases of Leishmaniasis.

Authors:  R W Ashford; P Desjeux; P Deraadt
Journal:  Parasitol Today       Date:  1992-03

8.  Intracellular parasite killing induced by electron carriers. I. Effect of electron carriers on intracellular Leishmania spp. in macrophages from different genetic backgrounds.

Authors:  J Mauel
Journal:  Mol Biochem Parasitol       Date:  1984-09       Impact factor: 1.759

9.  In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents.

Authors:  D Figgitt; W Denny; P Chavalitshewinkoon; P Wilairat; R Ralph
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 10.  Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.

Authors:  Z A Arlin
Journal:  Cancer Treat Rep       Date:  1983-11
View more
  4 in total

1.  Synthesis of novel Eu(III) luminescent probe based on 9- acridinecarboxylic acid skelton for sensing of ds-DNA.

Authors:  Hassan A Azab; Belal H M Hussein; Abdullah I El-Falouji
Journal:  J Fluoresc       Date:  2011-11-09       Impact factor: 2.217

2.  Microscopic observation of progressive immobilization of leishmania promastigotes in acridine orange stain.

Authors:  G S Barreca; M C Berlinghieri; F Foti; G Matera; A Foca
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

3.  Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi.

Authors:  K M Slunt; J M Grace; T L Macdonald; R D Pearson
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 4.  Evolution of Acridines and Xanthenes as a Core Structure for the Development of Antileishmanial Agents.

Authors:  Carlos F M Silva; Diana C G A Pinto; Pedro A Fernandes; Artur M S Silva
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.